open access

Vol 68, No 5 (2017)
Original paper
Submitted: 2016-10-24
Accepted: 2016-12-07
Published online: 2017-08-30
Get Citation

Osteoporosis associated selected single nucleotide polymorphisms frequency in HIV-infected and non-infected Polish population

Dorota Cecylia Bander1, Miłosz Parczewski1, Anna Urbańska2, Marta Bander2, Anhelli Syrenicz3, Marta Wawrzynowicz-Syczewska3
DOI: 10.5603/EP.a2016.0043
·
Pubmed: 27345147
·
Endokrynol Pol 2017;68(5):541-549.
Affiliations
  1. Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University in Szczecin, Poland
  2. Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, Poland
  3. Department of Endocrinology, Metabolic Diseases and Internal Medicine, Pomeranian Medical University in Szczecin, Poland

open access

Vol 68, No 5 (2017)
Original Paper
Submitted: 2016-10-24
Accepted: 2016-12-07
Published online: 2017-08-30

Abstract

Introduction: Osteoporosis poses significant risk for HIV infected subjects in the era of the long-term antiretroviral treatment. For this study frequency of the selected 11 single nucleotide polymorphisms (SNP single nucleotide polymorphism) previously associated with osteoporosis risk in HIV infected and uninfected cohorts was analysed. Association with the SNP variation and the risk of osteoporosis in the entire study and in HIV-infected cases was investigated.

Material and methods: The study included 568 patients (226 women and 342 men): 315 HIV-infected patients and 253 anti-HIV negative cases. Osteoporosis was confirmed using dual energy absorptiometry ionizing radiation (DXA) in eight HIV infected patients and three controls [odds ratio (OR): 7.66, 95% CI: 1.98–29.6; p = 0.001; relative risk (RR): 7.04, 95% CI: 1.98–25.97, p = 0.0019]. SNP assays performed for collagen type 1 (COL1A1) rs1800012, parathyroid hormone (PTH) rs9630182, estrogen receptor gene (ER1) rs2077647, rs3020314 and rs1884051, Vitamin D receptor (VDR) rs1544410 and rs731236, Osteoprotegerin rs4355801, LDL receptor protein (LRP5) rs3736228, RANK rs3018362 and CYP19A1 (aromatase) rs700518 using TaqMan SNP Genotyping Assay (Applied Biosystems) according to the manufacturer’s protocol. For statistics Statistica 12 software was used.

Results: Majority of allele frequencies for the studied polymorphisms were consistent with the Hardy-Weinberg equilibrium. CC homozygotes for ER1 rs2077647 were notably more common in HIV (+) cases compared to controls [OR: 2.29, 95%CI: 1.25–4.19, p = 0.003; RR: 2.11, 1.22–3.68, p = 0.0072]. Also GG homozygotes for ER1 rs1884051 were more common both in HIV(+) [OR: 2.57, 1.33–4.94, p = 0.0016; RR: 2.37, 1.29–4.36, p = 0.002] and in all patients with osteoporosis [OR 5.04, 1.24–20.4, p = 0.025; RR 3.94, 1.38–11.24, p = 0.043] . Additionally, in HIV (+) patients parathyroid hormone rs9630182 T allele was notably more common [OR: 1.4, 1.0–1.97, p = 0.024; RR: 1.15, 0.99–1.33, p = 0.029].

Conclusions: Genetic variability for the osteoporosis-associated SNPs was similar in HIV-infected patients and uninfected persons. ER1rs1884051 variants may be associated with the increased osteoporosis risk, but increased incidence of osteoporosis in HIV-infected compared to uninfected people seems to be weakly associated with investigated single nucleotide polymorphisms. Variation in the gene for the estrogen receptor ER1rs1884051 was significantly more frequent in patients with osteoporosis and more common in HIV infection.

Abstract

Introduction: Osteoporosis poses significant risk for HIV infected subjects in the era of the long-term antiretroviral treatment. For this study frequency of the selected 11 single nucleotide polymorphisms (SNP single nucleotide polymorphism) previously associated with osteoporosis risk in HIV infected and uninfected cohorts was analysed. Association with the SNP variation and the risk of osteoporosis in the entire study and in HIV-infected cases was investigated.

Material and methods: The study included 568 patients (226 women and 342 men): 315 HIV-infected patients and 253 anti-HIV negative cases. Osteoporosis was confirmed using dual energy absorptiometry ionizing radiation (DXA) in eight HIV infected patients and three controls [odds ratio (OR): 7.66, 95% CI: 1.98–29.6; p = 0.001; relative risk (RR): 7.04, 95% CI: 1.98–25.97, p = 0.0019]. SNP assays performed for collagen type 1 (COL1A1) rs1800012, parathyroid hormone (PTH) rs9630182, estrogen receptor gene (ER1) rs2077647, rs3020314 and rs1884051, Vitamin D receptor (VDR) rs1544410 and rs731236, Osteoprotegerin rs4355801, LDL receptor protein (LRP5) rs3736228, RANK rs3018362 and CYP19A1 (aromatase) rs700518 using TaqMan SNP Genotyping Assay (Applied Biosystems) according to the manufacturer’s protocol. For statistics Statistica 12 software was used.

Results: Majority of allele frequencies for the studied polymorphisms were consistent with the Hardy-Weinberg equilibrium. CC homozygotes for ER1 rs2077647 were notably more common in HIV (+) cases compared to controls [OR: 2.29, 95%CI: 1.25–4.19, p = 0.003; RR: 2.11, 1.22–3.68, p = 0.0072]. Also GG homozygotes for ER1 rs1884051 were more common both in HIV(+) [OR: 2.57, 1.33–4.94, p = 0.0016; RR: 2.37, 1.29–4.36, p = 0.002] and in all patients with osteoporosis [OR 5.04, 1.24–20.4, p = 0.025; RR 3.94, 1.38–11.24, p = 0.043] . Additionally, in HIV (+) patients parathyroid hormone rs9630182 T allele was notably more common [OR: 1.4, 1.0–1.97, p = 0.024; RR: 1.15, 0.99–1.33, p = 0.029].

Conclusions: Genetic variability for the osteoporosis-associated SNPs was similar in HIV-infected patients and uninfected persons. ER1rs1884051 variants may be associated with the increased osteoporosis risk, but increased incidence of osteoporosis in HIV-infected compared to uninfected people seems to be weakly associated with investigated single nucleotide polymorphisms. Variation in the gene for the estrogen receptor ER1rs1884051 was significantly more frequent in patients with osteoporosis and more common in HIV infection.

Get Citation

Keywords

polymorphism, SNP, osteoporosis, HIV

About this article
Title

Osteoporosis associated selected single nucleotide polymorphisms frequency in HIV-infected and non-infected Polish population

Journal

Endokrynologia Polska

Issue

Vol 68, No 5 (2017)

Article type

Original paper

Pages

541-549

Published online

2017-08-30

Page views

866

Article views/downloads

825

DOI

10.5603/EP.a2016.0043

Pubmed

27345147

Bibliographic record

Endokrynol Pol 2017;68(5):541-549.

Keywords

polymorphism
SNP
osteoporosis
HIV

Authors

Dorota Cecylia Bander
Miłosz Parczewski
Anna Urbańska
Marta Bander
Anhelli Syrenicz
Marta Wawrzynowicz-Syczewska

References (36)
  1. Thomas J, Doherty SM. HIV infection--a risk factor for osteoporosis. J Acquir Immune Defic Syndr. 2003; 33(3): 281–291.
  2. Pollock E, Klotsas AE, Compston J, et al. Bone health in HIV infection. Br Med Bull. 2009; 92: 123–133.
  3. Coaccioli S, Del Giorno R, Crapa G, et al. Study of bone metabolism in patients with chronic HIV infection. Clin Ter. 2009; 160(6): 451–456.
  4. Paccou J, Viget N, Legrout-Gérot I, et al. Bone loss in patients with HIV infection. Joint Bone Spine. 2009; 76(6): 637–641.
  5. Grijsen ML, Vrouenraets SME, Steingrover R, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS. 2010; 24(14): 2233–2238.
  6. Witas HW, Wujcicka WI. Genetyczne wyznaczniki osteoporozy. Post Bol Kom. 2007; 34(3): 495–509.
  7. Ferrari S. Human genetics of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008; 22(5): 723–735.
  8. van Meurs JBJ, Trikalinos TA, Ralston SH, et al. GENOMOS Study. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008; 299(11): 1277–1290.
  9. Kitjaroentham A, Hananantachai H, Phonrat B, et al. Low density lipoprotein receptor-related protein 5 gene polymorphisms and osteoporosis in Thai menopausal women. J Negat Results Biomed. 2016; 15(1): 16.
  10. Tu P, Duan P, Zhang RS, et al. Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women. Osteoporos Int. 2015; 26(1): 179–185.
  11. Yoshida S, Ikari K, Furuya T, et al. An osteoprotegerin gene polymorphism is associated with an increased risk of hip fracture in Japanese patients with rheumatoid arthritis: results from the IORRA Observational Cohort Study. PLoS One. 2014; 9(8): e104587.
  12. Zavala-Cerna MG, Moran-Moguel MC, Cornejo-Toledo JA, et al. Osteoprotegerin Polymorphisms in a Mexican Population with Rheumatoid Arthritis and Generalized Osteoporosis: A Preliminary Report. J Immunol Res. 2015; 2015: 376197.
  13. Richards JB, Rivadeneira F, Inouye M, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet. 2008; 371(9623): 1505–1512.
  14. Richards JB, Kavvoura FK, Rivadeneira F, et al. Genetic Factors for Osteoporosis Consortium. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med. 2009; 151(8): 528–537.
  15. Paternoster L, Ohlsson C, Sayers A, et al. OPG and RANK polymorphisms are both associated with cortical bone mineral density: findings from a metaanalysis of the Avon longitudinal study of parents and children and gothenburg osteoporosis and obesity determinants cohorts. J Clin Endocrinol Metab. 2010; 95(8): 3940–3948.
  16. Urano T, Inoue S. Genetics of osteoporosis. Biochem Biophys Res Commun. 2014; 452(2): 287–293.
  17. Rivadeneira F, Styrkársdottir U, Estrada K, et al. Genetic Factors for Osteoporosis (GEFOS) Consortium. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009; 41(11): 1199–1206.
  18. August R, Gumprecht J, Karasek D, et al. Polimorfizm A, B i T genu receptora dla witaminy D a gęstość tkanki kostnej u chorych na cukrzycę i terminalną niewydolność nerek leczonych nerko zastępczo. Diab Doś Klin. 2003; 3(1): 61–70.
  19. Majchrzycki M, Bartkowiak-Wieczorek J, Wolski H, et al. Polymorphisms of collagen 1A1 (COL1A1) gene and their relation to bone mineral density in postmenopausal women. Polish Gynaecology. 2015; 86(12).
  20. Saadi HF, Nagelkerke N, Benedict S, et al. Predictors and relationships of serum 25 hydroxyvitamin D concentration with bone turnover markers, bone mineral density, and vitamin D receptor genotype in Emirati women. Bone. 2006; 39(5): 1136–1143.
  21. Ardawi MSM, Qari MH, Rouzi AA, et al. Vitamin D status in relation to obesity, bone mineral density, bone turnover markers and vitamin D receptor genotypes in healthy Saudi pre- and postmenopausal women. Osteoporos Int. 2011; 22(2): 463–475.
  22. Boroňová I, Bernasovská J, Mačeková S, et al. TNFRSF11B gene polymorphisms, bone mineral density, and fractures in Slovak postmenopausal women. J Appl Genet. 2015; 56(1): 57–63.
  23. Hein A, Bayer CM, Schrauder MG, et al. Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients. Geburtshilfe und Frauenheilkunde. 2014; 74(S 01).
  24. Ho-Pham LT, Nguyen SC, Tran B, et al. Contributions of Caucasian-associated bone mass loci to the variation in bone mineral density in Vietnamese population. Bone. 2015; 76: 18–22.
  25. Hu Ww, He Jw, Zhang H, et al. No association between polymorphisms and haplotypes of COL1A1 and COL1A2 genes and osteoporotic fracture in postmenopausal Chinese women. Acta Pharmacol Sin. 2011; 32(7): 947–955.
  26. Liu J, Hoppman N, O'Connell JR, et al. A functional haplotype in EIF2AK3, an ER stress sensor, is associated with lower bone mineral density. J Bone Miner Res. 2012; 27(2): 331–341.
  27. Luo L, Xia W, Nie M, et al. Association of ESR1 and C6orf97 gene polymorphism with osteoporosis in postmenopausal women. Mol Biol Rep. 2014; 41(5): 3235–3243.
  28. Mo XB, Lu X, Zhang YH, et al. Gene-based association analysis identified novel genes associated with bone mineral density. PLoS One. 2015; 10(3): e0121811.
  29. Napoli N, Rastelli A, Ma C, et al. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer. Bone. 2013; 55(2): 309–314.
  30. Qin L, Liu Y, Wang Ya, et al. Computational Characterization of Osteoporosis Associated SNPs and Genes Identified by Genome-Wide Association Studies. PLoS One. 2016; 11(3): e0150070.
  31. Rojano-Mejía D, Coral-Vázquez RM, Espinosa LC, et al. JAG1 and COL1A1 polymorphisms and haplotypes in relation to bone mineral density variations in postmenopausal Mexican-Mestizo Women. Age (Dordr). 2013; 35(2): 471–478.
  32. Shang DP, Lian HY, Fu DP, et al. Relationship between estrogen receptor 1 gene polymorphisms and postmenopausal osteoporosis of the spine in Chinese women. Genet Mol Res. 2016; 15(2).
  33. Shang M, Lin Li, Cui H. Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women. Clin Biochem. 2013; 46(15): 1493–1501.
  34. Song JF, Jing ZZ, Hu W, et al. Association between single nucleotide polymorphisms of the osteoprotegerin gene and postmenopausal osteoporosis in Chinese women. Genet Mol Res. 2013; 12(3): 3279–3285.
  35. Wu Ju, Shang DP, Yang S, et al. Association between the vitamin D receptor gene polymorphism and osteoporosis. Biomed Rep. 2016; 5(2): 233–236.
  36. The National Center for Biotechnology Information, US National Library of Medicine, dbSNP Short Genetic Variations. https://www.ncbi.nlm.nih.gov/SNP/ (2016).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl